Keyphrases
18F-fluorodeoxyglucose (18F-FDG)
9%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
100%
Advanced Solid Tumors
9%
Akt Activation
18%
AKT1
18%
Anticancer Agents
9%
Cancer Treatment
18%
Clinical Outcomes
100%
Clinical Response
9%
Clinical Trials
9%
Computed Tomography
9%
European Organizations
18%
FDG Positron Emission Tomography
100%
Glucose Transporter 1 (GLUT1)
18%
Glycolysis
9%
Inhibitor Therapy
100%
Mammalian Target of Rapamycin Inhibition
9%
Metabolic Disease
9%
MTOR Complex 2 (mTORC2)
9%
MTOR Inhibitor
100%
Murine Xenograft Model
9%
Murine Xenografts
9%
Objective Response
9%
Pathway Activity
100%
Pharmacodynamic Markers
9%
Plasma Membrane
9%
Positron Emission Tomography
18%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
Predictive Marker
9%
Progressive Disease
18%
Proliferative Response
9%
Quantitative Change
9%
Rapamycin
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
Small Animal
9%
Temsirolimus
9%
Tumor
18%
Tumor Patients
9%
Xenograft Tumor Model
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anticancer Drug
20%
Clinical Study
20%
Clinical Trial
20%
Diseases
40%
Fluorodeoxyglucose F 18
100%
Glucose Transporter 1
40%
Malignant Neoplasm
40%
Mammalian Target of Rapamycin
20%
Mammalian Target of Rapamycin Complex 2
20%
Mammalian Target of Rapamycin Inhibitor
100%
Metabolic Disorder
20%
Neoplasm
40%
Pharmacodynamics
20%
Preclinical Study
40%
Protein Kinase B
100%
Rapamycin
20%
Solid Malignant Neoplasm
40%
Temsirolimus
20%
Tumor Model
20%
Medicine and Dentistry
Anticancer Drug
8%
Cancer Treatment
16%
Cell Membrane
8%
Clinical Trial
8%
Computer Assisted Tomography
8%
Fluorodeoxyglucose F 18
100%
Glucose Transporter 1
16%
Mammalian Target of Rapamycin Complex 2
8%
Mammalian Target of Rapamycin Inhibitor
100%
Mechanistic Target of Rapamycin
8%
Neoplasm
16%
Pharmacodynamics
8%
Positron Emission Tomography
100%
Positron Emission Tomography-Computed Tomography
8%
Predictive Marker
8%
Progressive Disease
16%
Protein Kinase B
100%
Rapamycin
8%
Response Evaluation Criteria in Solid Tumors
8%
Solid Malignant Neoplasm
8%
Temsirolimus
8%
Tumor Model
8%
Water-Electrolyte Imbalance
8%
Xenograft
16%
Immunology and Microbiology
Cell Membrane
8%
Computer Assisted Tomography
8%
Mammalian Target of Rapamycin Complex 2
8%
Pharmacodynamics
8%
Positron Emission Tomography
100%
Positron Emission Tomography-Computed Tomography
8%
Preclinical Study
16%
Sirolimus
100%
Temsirolimus
8%
Xenograft
16%